{"id":"W3198154413","doi":"10.1161/circulationaha.121.056810","title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; American Regent; St. Jude Medical; Esperion Therapeutics; Idorsia Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Duke Clinical Research Institute; Astellas Pharma; Eisai; Cleveland Clinic; Bristol-Myers Squibb; CryoLife; Medicines Company; Regado Biosciences; Novo Nordisk; MyoKardia; Daiichi-Sankyo; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Boston VA Research Institute; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Prostate cancer; Randomized controlled trial; Prostate; Cancer; Urology; Gynecology; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003282435,0.0008486632,0.002314494,0.0003519726,0.0003627005,0.001328641,0.0006673739,0.001241074,0.00598683],"category_scores_gemma":[0.005829759,0.0002655367,0.001670549,0.0004775897,0.00104352,0.0009079385,0.0004624733,0.002270172,0.0003042511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000640967,"about_ca_system_score_gemma":0.0007877718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005152465,"about_ca_topic_score_gemma":0.0009641135,"domain_scores_codex":[0.9980069,0.001430949,0.00009476335,0.0002325588,0.0001429806,0.00009180225],"domain_scores_gemma":[0.9967679,0.001366325,0.001013713,0.0001904693,0.0001436504,0.0005179323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9687262,0.001366268,0.00244371,0.001243395,0.002131736,0.00004481974,0.00006801482,0.0002888785,0.0007817171,0.0003435175,0.00134866,0.02121305],"study_design_scores_gemma":[0.9694198,0.02299217,0.003401833,0.0001451763,0.001412375,0.00005736231,0.00006113779,0.0003399054,0.0003521375,0.0004453844,0.001356804,0.00001578648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9595555,0.02897235,0.0006171227,0.003085151,0.000982221,0.0009972126,0.001148638,0.00007103341,0.004570674],"genre_scores_gemma":[0.9878343,0.004623401,0.001188175,0.00194779,0.0007882264,0.0008229793,0.0008966844,0.00001655121,0.001881935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00598683,"threshold_uncertainty_score":0.020028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01695433379412681,"score_gpt":0.2626105683141965,"score_spread":0.2456562345200697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}